Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule

摘要: A study designed to correlate clinical and pharmacologic observations was undertaken in 96 patients treated with adriamycin. The basic dosage schedule 60 mg/m2 I.V. q 3 weeks. Pharmacokinetic studies showed a prolonged plasma half-life, low urinary excretion, undetectable levels CSF. Patients significantly impaired liver function had marked elevation prolongation of drug associated severe toxicity unless reduced by 50-7596. Of the 82 evaluable patients, 10/25 sarcomas, 9/31 carcinomas, 15/26 hematologic malignancies have achieved complete or partial remission. An additional 22/48 improved. Six solid tumors progressive CNS disease while responding systemically. Adriamycin can he used relative safety high efficacy that resulted from studies. Dosage reduction is essential avoid life-threatening toxicity.